| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers M > Headlines for Molecular Insight Pharmaceuticals, Inc. > News item |
Molecular Insight marks $1.33 million net loss for Dec. 10 to Dec. 31
By Caroline Salls
Pittsburgh, Jan. 26 - Molecular Insight Pharmaceuticals, Inc. reported a $1.33 million net loss for the period of Dec. 10 to Dec. 31 on $144,560 in grant revenue, according to its monthly operating report filed Wednesday with the Securities and Exchange Commission.
The company had $14.32 million in cash and cash equivalents at Dec. 31.
Molecular Insight, a Cambridge, Mass.-based clinical-stage biopharmaceutical company focused on molecular medicine, filed for bankruptcy on Dec. 9 in the U.S. Bankruptcy Court for the District of Massachusetts. The Chapter 11 case number is 10-23355.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.